About
Biologics, Monoclonal Antibodies
Areas of Focus
Categories
Biologics & BiopharmaceuticalAntibodyBoston & New England
Team (22)
Aaron Young
Chief Intellectual Property Officer
Kiniksa Pharmaceuticals
team_member
Barry D. Quart
Director
Kiniksa Pharmaceuticals
team_member
Eben Tessari
Chief Operating Officer
Kiniksa Pharmaceuticals
executive
Felix Baker
Lead Director
Kiniksa Pharmaceuticals
lead_independent_director
G. Bradley Cole
Director
Kiniksa Pharmaceuticals
team_member
Jennifer Ring
VP Program & Alliance Management
Kiniksa Pharmaceuticals
executive
Clinical Trials (17)
View allTotal Trials
17
As Lead Sponsor
7
As Collaborator
10
Total Enrollment
2,806
By Phase
PHASE2/PHASE3: 2PHASE2: 9PHASE1: 1PHASE3: 2PHASE1/PHASE2: 2
By Status
COMPLETED: 14RECRUITING: 1TERMINATED: 1ACTIVE_NOT_RECRUITING: 1
Clinical Trials Pipeline17 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
Today
Hover over trial bars to see details
Recent Trials
NCT07010159Collaborator
Phase 2/3 Study of KPL-387 in Recurrent Pericarditis
PHASE2/PHASE3Recruiting
165 participants
Started: Oct 31, 2025 · Completed: Dec 31, 2029
NCT06531395Collaborator
A Study to Evaluate the Efficacy and Safety of Abiprubart in Participants With Sjögren's Disease
PHASE2Terminated
3 participants
Started: Jul 17, 2024 · Completed: May 1, 2025
NCT05198310Lead Sponsor
Study to Assess the Safety, Pharmacokinetics, and Efficacy of KPL-404 in Participants With Rheumatoid Arthritis With Inadequate Response or Intolerance to at Least One Biologic Disease-modifying Anti-rheumatic Drug or a Janus Kinase Inhibitor
PHASE2Completed
145 participants
Started: Dec 14, 2021 · Completed: May 6, 2024
NCT04687358Collaborator
REgiStry Of the NAtural History of recurreNt periCarditis in pEdiatric and Adult Patients
N/AActive, not recruiting
500 participants
Started: Mar 16, 2021 · Completed: Feb 28, 2026
NCT04463004Collaborator
Mavrilimumab to Reduce Progression of Acute Respiratory Failure in COVID-19 Pneumonia and Systemic Hyper-inflammation
PHASE2Completed
2 participants
Started: Sep 2, 2020 · Completed: Nov 30, 2020
Locations (1)
Headquarters
Lexington, MA, United States
Map
Loading map...